Ratings by Piper Sandler (Kelsey Goodwin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/7/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2026 | Obsidian Therapeutics | OBX | New Coverage | Overweight (N/A) |
0.04 (13.93) |
34725% | Details | |
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Neutral (Overweight) |
88.49 (123.96) |
40.08% | Details | |
| 5/27/2026 | LeonaBio | LONA | New Coverage | Overweight (N/A) |
10.33 (5.67) |
-45.11% | Details | |
| 5/15/2026 | Tango Therapeutics Inc. | TNGX | Downgrade | Neutral (Overweight) |
25.51 (26.98) |
5.76% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2026 | Relmada Therapeutics Inc | RLMD | New Coverage | Overweight (N/A) |
6.07 (3.21) |
-47.12% | Details | |
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Neutral (Overweight) |
12.78 (21.53) |
68.47% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2026 | Protera Therapeutics | TARA | New Coverage | Overweight (N/A) |
5.39 (2.50) |
-53.62% | Details | |
| 1/7/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Overweight (N/A) |
8.15 (13.85) |
69.94% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Overweight (N/A) |
25.10 (7.05) |
-71.91% | Details | |
| 1/7/2026 | Erasca Inc | ERAS | New Coverage | Overweight (N/A) |
3.49 (14.49) |
315.19% | Details | |
| 11/17/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Overweight (N/A) |
4.01 (2.08) |
-48.13% | Details | |
| 11/5/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/19/2025 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
75.01 (88.49) |
17.97% | Details | |
| 8/19/2025 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
6.77 (25.51) |
276.81% | Details | |
| 8/19/2025 | UroGen Pharma | URGN | New Coverage | Overweight (N/A) |
19.71 (35.48) |
80.01% | Details | |
| 8/19/2025 | Summit Therapeutics plc | SMMT | New Coverage | Neutral (N/A) |
26.69 (15.83) |
-40.69% | Details | |
| 8/19/2025 | Revolution | RVMD | New Coverage | Overweight (N/A) |
36.32 (194.28) |
434.91% | Details | |
| 8/19/2025 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
25.11 (16.93) |
-32.58% | Details | |
| 8/19/2025 | Day One Biopharmaceuticals | DAWN | New Coverage | Overweight (N/A) |
52.88 (12.78) |
-75.83% | Details | |
| 8/19/2025 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
25.70 (62.24) |
142.18% | Details | |
| 8/19/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
11.64 (17.91) |
53.87% | Details |
